Please login to the form below

Not currently logged in
Email:
Password:

HER3 inhibitors

This page shows the latest HER3 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Daiichi pulls study of patritumab in lung cancer

Daiichi pulls study of patritumab in lung cancer

Other companies working on HER3 inhibitors include Merrimack Pharma, whose seribantumab (MM-121) candidate is in phase III, as well as GlaxoSmithKline with GKS2849330 (phase I) and Roche's Genentech unit ... which has a dual HER3/EGFR inhibitor called

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics